Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.60 USD
+0.04 (0.72%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALIM 5.60 +0.04(0.72%)
Will ALIM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALIM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALIM
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
ALIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
New Strong Sell Stocks for March 13th
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Other News for ALIM
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
Alimera Sciences just downgraded at Alliance Global Partners, here's why
Alimera Sciences just downgraded at Maxim, here's why
Hold Rating Maintained Amid ANI Pharmaceuticals Acquisition of Alimera Sciences
Alimera Sciences just downgraded at H.C. Wainwright, here's why